Roche’s Announcement Regarding New Data of Enspryng for Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD)
2026-04-22 · Chugai Pharmaceutical · original chugai-pharm.co.jp ↗
TOKYO, April 22, 2026 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that Roche issued a media release today, regarding new data from the METEOROID study of Enspryng® (generic name: satralizumab) for myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). The data were presented on April 21 at the 2026 American Academy of Neurology Annual Meeting in Chicago. Please refer to the link below for details of the media release: Roche’s ENSPRYNG (satralizumab) reduces risk of relapses by 68% demonstrating potential to become first treatment for MOGAD https://www.roche.com/media/releases/med-cor-2026-04-21b Trademarks used or mentioned in this release are protected by laws.
The release as fetched from its publisher. chugai-pharm.co.jp ↗